


TRANSITION OF EVOGAM TO HIZENTRA AU

 **HIZENTRA and HIZENTRA AU are different products**

CSL Behring is replacing EVOGAM with HIZENTRA AU. The transition of patients from EVOGAM to HIZENTRA AU will commence **from 2 August 2023** with EVOGAM expected to no longer be available to order from October 2023.

What is changing?

EVOGAM is being replaced with HIZENTRA AU. HIZENTRA AU will be made using plasma from Australian donors to the same high safety and quality standards used to produce EVOGAM.



CURRENT PRODUCT

EVOGAM 16% 0.8g/5mL
EVOGAM 16% 3.2g/20mL

REPLACEMENT PRODUCT

HIZENTRA AU 20% 1g/5mL (BloodNet ID: 149)
HIZENTRA AU 20% 4g/20mL (BloodNet ID: 150)

Note that HIZENTRA and HIZENTRA AU are different products and that you must carefully check that you are selecting the correct product. HIZENTRA AU can be identified by the Lifeblood logo at the bottom of the carton or vial.

Why is EVOGAM transitioning to HIZENTRA AU?

Under the National Fractionation Agreement for Australia CSL Behring is expanding its manufacturing facility to support the processing of Australia's growing plasma collections. This will allow increased capacity and continued reliability.

As part of this expansion CSL Behring will change how it manufactures five of Australia's domestic plasma products to align with its global manufacturing processes. More information can be found by scanning the QR code or here: [Transition of Australia's domestic plasma products \(shorturl.at/gvAUZ\)](https://shorturl.at/gvAUZ).



How and when will the transition happen?



Treating medical specialists will need to manually transition EVOGAM patients to HIZENTRA AU in BloodSTAR

From 2 August 2023

Health providers are asked to start transitioning their EVOGAM patients to HIZENTRA AU from 2 August 2023. EVOGAM patients can be transitioned by submitting a dose change in BloodSTAR.

From October 2023

EVOGAM is anticipated to no longer be available for ordering. Any EVOGAM patients remaining in BloodSTAR will be automatically transitioned to HIZENTRA AU.

HIZENTRA AU will be available in BloodNet and BloodSTAR from 2 August 2023. From this date EVOGAM patients can start to be transitioned to HIZENTRA AU.

Treating medical specialists will need to manually transition EVOGAM patients to HIZENTRA AU via a dose change request in BloodSTAR. This is to allow health providers flexibility around scheduling the transition of these patients.

As with all authorisations, clinicians may select a product other than HIZENTRA AU provided there is a valid clinical reason, for example where a patient has a contraindication to a product.

Clinicians are encouraged to discuss the change to HIZENTRA AU with patients in advance of the move. This is recommended particularly as there are some differences in the administration and concentration of HIZENTRA AU compared to EVOGAM. Information to assist with this can be found at the bottom of this handout.

Currently, it is expected that facilities will still be able to order EVOGAM up to late September 2023. Note that it is anticipated that from October 2023, any patients remaining on EVOGAM in BloodSTAR will be automatically transitioned to HIZENTRA AU. We will notify you around 1 month before this happens.

What should I do to prepare?

Clinicians

- Ensure that your EVOGAM patients are aware of the upcoming change to their subcutaneous immunoglobulin product. Resources to assist with this can be found at the bottom of this handout.
- Ensure that your hospital or treatment facility has infusion protocols for HIZENTRA AU in place. CSL Behring can assist with this on 1800 642 865 or medicalinformation@cslbehring.com.au.

- If your patient has previously had a reaction to HIZENTRA ensure a **Do Not Prescribe** alert for HIZENTRA is added to the patient's record in BloodSTAR. While HIZENTRA and HIZENTRA AU are different products and patients may not react to both products, they share some similarities and a cautious approach is recommended. You may want to consider whether it is appropriate to prescribe an alternate immunoglobulin product.

Dispensers

- Add the HIZENTRA AU product codes to your BloodNet interfaced Laboratory Information Management System.

REPLACEMENT PRODUCT	BLOODNET ID	PRODUCT ID
HIZENTRA AU 1g/5mL	149	1000572
HIZENTRA AU 4g/20mL	150	1000573

- Scan the test barcodes to ensure your system is configured to read them. Sample barcodes can be found here: <https://www.blood.gov.au/barcoding>.
- Discuss with your treating teams their plan to transition patients so you can ensure you have enough inventory to meet requests.

What should I do during the transition?

Clinicians

- Note that HIZENTRA and HIZENTRA AU are different products** and care must be taken to ensure the correct product is given.
- Update the patient's script and consent to receive treatment as per your local guidelines.
- Submit a dose change request in BloodSTAR for HIZENTRA AU. If there is a clinical reason to do so, an alternate immunoglobulin product can be selected.
- Note dose calculations in BloodSTAR will be automatically updated and rounded to the nearest vial size as is the usual BloodSTAR functionality.
- Treating medical specialists are encouraged to liaise with the teams responsible for patient scheduling to ensure sufficient time to support patients transitioning.
- Inform your dispensing team of your planned timing of EVOGAM patient transitions to inform their product ordering.
- Current dispense requests for a patient on an active BloodSTAR Planning Sheet will be cancelled once a HIZENTRA AU dose change request has been approved for that patient. A new Planning Sheet will need to be created to include the HIZENTRA AU dispense requests. This can be done by someone with a Nurse/Midwife role in BloodSTAR.

Dispensers

- Note that HIZENTRA and HIZENTRA AU are different products** and care must be taken to ensure the correct product is dispensed.
- From 2 August 2023 your Stock Order templates in BloodNet can be updated and orders placed for HIZENTRA AU. The update to the template must be completed by a BloodNet Facility Administrator.

- In liaison with your treating teams, continue to order EVOGAM to support the transition of your facility's patients. Based on current demand and inventory levels it is anticipated that EVOGAM will be available to order up to late September 2023. You will be notified around 1 month before EVOGAM will no longer be available.
- If your facility has EVOGAM inventory that is not needed, please reach out to your local area network as there may be a nearby hospital or treatment facility that the inventory can be transferred to. The transfer can be completed in BloodNet through the Stock Movement function.

Additional considerations

CSL Cares Patient Support Program

CSL Behring offers a program which provides patient education and training in the home. Contact CSL Behring via phone on 1800 442 744 or fax 1800 734 989 or email support@cslbehringcares.com.au for more information about this program.

Where can I find out more information?

Some materials to assist with discussions with patients can be found here:

- Handout about the transition:
<https://www.blood.gov.au/system/files/documents/HIZENTRA%20AU%20Patient%20Information%20Sheet.pdf>
- Pamphlet on switching immunoglobulin products:
<https://www.blood.gov.au/sites/default/files/Switching%20Immunoglobulin%20Products%20Pamphlet.pdf>
- Educational materials on HIZENTRA AU: <https://hcp.cslbehring.com.au/> (select the red Immunoglobulin tile)

If you would like to know more about HIZENTRA AU including consumables, healthcare professionals can access:

- Educational material on through the CSL Behring Resource Hub and on its website:
<https://hcp.cslbehring.com.au/>
<https://www.cslbehring.com.au/products/products-list>
- CSL Behring can also be contacted on 1800 642 865 or medicalinformation@cslbehring.com.au

If you need help with actioning something in BloodSTAR, tip sheets can be found here:

- <https://www.blood.gov.au/bloodstar-support-materials>

If you need help with actioning something in BloodNet, tip sheet can be found here:

- <https://www.blood.gov.au/bloodnet-support-materials>

Points of Contact

Product and administration questions, including reporting of adverse events

- the manufacturer CSL Behring on **1800 642 865** or medicalinformation@cslbehring.com.au

BloodNet, BloodSTAR and general questions about the transition

- the National Blood Authority on **13 000 BLOOD (13 000 25663)** or supply.management.plasma@blood.gov.au

General questions about BloodSTAR authorisations and product ordering

- your local Australian Red Cross Lifeblood Customer Service team (<https://www.lifeblood.com.au/contact>)